CAS: 1171919-00-8 - 2-chloro-3,5-diiodopyridin-4-amine
Formula:C5H3ClI2N2
InChI:InChI=1S/C5H3ClI2N2/c6-5-3(8)4(9)2(7)1-10-5/h1H,(H2,9,10)
InChI key:InChIKey=ADBYPUPWCVKWCP-UHFFFAOYSA-N
SMILES:ClC1=NC=C(I)C(N)=C1I
| Brand | Product data | Purity | Price range | Estimated delivery |
|---|---|---|---|---|
 | 4-Pyridinamine, 2-chloro-3,5-diiodo- REF: IN-DA000DW6CAS: 1171919-00-8 | 97% | To inquire | Mon 16 Dec 24 |
 | 2-Chloro-3,5-diiodo-4-pyridinamine REF: 54-OR301296CAS: 1171919-00-8 | 0.95 | 198.00 €~5,260.00 € | Mon 23 Dec 24 |
 | 2-Chloro-3,5-diiodopyridin-4-amine REF: 10-F432432CAS: 1171919-00-8 | 95.0% | To inquire | Fri 27 Dec 24 |
 | 2-Chloro-3,5-diiodo-4-pyridinamine REF: 3D-WWB91900CAS: 1171919-00-8 | Min. 95% | - - - | Discontinued product |
4-Pyridinamine, 2-chloro-3,5-diiodo-
CAS:1171919-00-8
Formula:
C5H3ClI2N2
Purity:
97%
Color and Shape:
Solid
Molecular weight:
380.3527
Ref: IN-DA000DW6
| 1g | 75.00 € | ||
| 5g | 179.00 € | ||
| 10g | 218.00 € | ||
| 25g | 635.00 € | ||
| 100g | To inquire | ||
| 100mg | 38.00 € | ||
| 250mg | 48.00 € | ||
| 500mg | 64.00 € |
Estimated delivery in United States, on Monday 16 Dec 2024
Ref: 54-OR301296
| 1g | 302.00 € | ||
| 5g | 859.00 € | ||
| 10g | 1,315.00 € | ||
| 25g | 2,893.00 € | ||
| 50g | 5,260.00 € | ||
| 500mg | 198.00 € |
Estimated delivery in United States, on Monday 23 Dec 2024
Ref: 10-F432432
| 1g | To inquire | ||
| 5g | To inquire | ||
| 10g | To inquire | ||
| 25g | To inquire | ||
| 250mg | To inquire | ||
| 500mg | To inquire |
Estimated delivery in United States, on Friday 27 Dec 2024
2-Chloro-3,5-diiodo-4-pyridinamine
CAS:1171919-00-8
2-Chloro-3,5-diiodo-4-pyridinamine is an antimycobacterial agent that acts as an inhibitor of the enzyme mycobacterial synthetase. …
Formula:
C5H3ClI2N2
Purity:
Min. 95%
Molecular weight:
380.35 g/mol
Ref: 3D-WWB91900
| 1g | Discontinued | Request information | |
| 5g | Discontinued | Request information | |
| 10g | Discontinued | Request information | |
| 250mg | Discontinued | Request information | |
| 500mg | Discontinued | Request information |
